Insmed Inc [INSM] stock is trading at $71.70, up 2.49%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The INSM shares have gain 0.42% over the last week, with a monthly amount drifted -1.46%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Insmed Inc [NASDAQ: INSM] stock has seen the most recent analyst activity on April 23, 2024, when Truist initiated its Buy rating and assigned the stock a price target of $48. Previously, Wolfe Research started tracking the stock with Outperform rating on February 15, 2024, and set its price target to $42. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $55 on the stock. Guggenheim initiated its recommendation with a Buy and recommended $50 as its price target on July 26, 2023. Mizuho started tracking with a Buy rating for this stock on December 09, 2022, and assigned it a price target of $28. In a note dated December 07, 2022, Barclays initiated an Overweight rating and provided a target price of $37 on this stock.
Insmed Inc [INSM] stock has fluctuated between $21.92 and $80.53 over the past year. Currently, Wall Street analysts expect the stock to reach $76.25 within the next 12 months. Insmed Inc [NASDAQ: INSM] shares were valued at $71.70 at the most recent close of the market. An investor can expect a potential return of 6.35% based on the average INSM price forecast.
Analyzing the INSM fundamentals
Insmed Inc [NASDAQ:INSM] reported sales of 328.61M for the trailing twelve months, which represents a growth of 16.98%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -2.03%, Pretax Profit Margin comes in at -2.43%, and Net Profit Margin reading is -2.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is 3.07 and Total Capital is -0.52. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 34.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 69.94 points at the first support level, and at 68.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 72.61, and for the 2nd resistance point, it is at 73.51.
Ratios To Look Out For
For context, Insmed Inc’s Current Ratio is 2.71. Further, the Quick Ratio stands at 2.53, while the Cash Ratio is 2.38. Considering the valuation of this stock, the price to sales ratio is 37.50, the price to book ratio is 307.84.
Transactions by insiders
Recent insider trading involved Smith Michael Alexander, Chief Legal Officer, that happened on Sep 13 ’24 when 27871.0 shares were sold. Chief Medical Officer, Flammer Martina M.D. completed a deal on Sep 13 ’24 to sell 26969.0 shares. Meanwhile, Chief Medical Officer Flammer Martina M.D. sold 13436.0 shares on Sep 16 ’24.
